Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

By C. Bonner, J. Kerr-Conte, V. Gmyr, G. Quéniat, E. Moerman, J. Thévenet, C. Beaucamps, N. Delalleau, Iuliana Popescu, W. Malaisse and 5 more. Nature Medicine, 2015

628 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/889c0daec8bb9ea0c0fad920783cf5e7ae365046

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. E. Ferrannini

In Surgery

1. E. Ferrannini

Citations in the corpus

• Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes (2016, background): “Moreover, recent in vitro and ex vivo work has suggested that inhibition of SGLT2 with dapagliflozin in pancreatic a-cells directly triggers glucagon secretion (10).”